Cohera Medical’s Novel Sealant Picked For FDA 'Expedited Access'
This article was originally published in The Gray Sheet
Executive Summary
FDA launched its new Expedited Access Pathway in April, and Cohera Medical is now the first company to announce participation for its Sylys Surgical Sealant. Under the program, Cohera hopes to use an interim trial analysis to accelerate the product's path to market.
You may also be interested in...
Shortened ‘Cures’ Draft Retains Breakthrough Pathway, Device Reforms
But the April 29 updated draft of the broad-based House reform package for medical innovation is missing some significant items floated earlier this year, including a Medicare breakthrough device program, a revamp of diagnostics regulations and device supply-chain security reform.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.